NASDAQ$SHC
Sotera Health Company · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Sotera Health's third-quarter results for 2021 showed revenue growth, driven by strong performance in Sterigenics and Nordion segments, while Nelson Labs experienced a slight revenue decrease due to reduced pandemic-related demand.
Sotera Health reported a 13.1% increase in net revenues to $226 million for the third quarter of 2021, compared to $200 million in the same period last year. Net income attributable to Sotera Health was $27 million, or $0.10 per diluted share, compared to net income of $0.01 million, or $0.00 per diluted share in the third quarter of 2020. Adjusted EBITDA increased by 16.1% to $117 million. The company is narrowing its full-year 2021 revenue growth outlook to 12%-14% and Adjusted EBITDA growth to 13%-14%.
- Net revenues for Q3 2021 increased by 13% to $226 million compared to Q3 2020.
- Net income for Q3 2021 was $27 million, or $0.10 per diluted share, compared to $0.01 million, or $0.00 per diluted share in Q3 2020.
- Adjusted EBITDA for Q3 2021 increased by 16% to $117 million compared to Q3 2020.
- Adjusted EPS for Q3 2021 was $0.21, an increase of $0.12 compared to Q3 2020.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$226M
Revenue by segment
Sotera Health · $226M total across 3 segments · Q3 2021
- Sterigenics$145M—64.3%
- Nelson Labs$52.1M—23.0%
- Nordion$28.8M—12.7%
Forward guidance
Sotera Health is updating its 2021 outlook and expects net revenues in the range of $920 million - $930 million, representing growth of 12% - 14%, and Adjusted EBITDA of $475 million - $480 million, representing growth of 13% - 14%. They anticipate an Adjusted EPS of $0.87 - $0.88.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro